OR5H1 Antibody

What is OR5H1 and what biological functions does it serve?

OR5H1 (Olfactory receptor 5H1) is a member of the olfactory receptor family, which belongs to the G-protein coupled receptor (GPCR) superfamily. These proteins are primarily involved in odorant recognition and signal transduction pathways in olfactory sensory neurons. While its primary function relates to odorant reception, recent research suggests potential roles beyond olfaction, particularly in immune modulation and tumor microenvironment interactions.

Similar to the findings with OR10H1, which has been shown to function as an immune checkpoint in cancer, OR5H1 may have broader biological significance than previously thought. Research indicates that olfactory receptors can modulate cAMP-dependent signaling pathways, which have implications for T cell activity and tumor immunity . The molecular structure of OR5H1 positions it as a multi-pass membrane protein, predominantly localized to the cell membrane .

What are the key specifications of commercially available OR5H1 antibodies?

OR5H1 antibodies are predominantly available as rabbit polyclonal immunoglobulins designed for research applications. Based on current research tools, these antibodies demonstrate the following specifications:

These antibodies are typically generated using synthetic peptides corresponding to amino acids 262-311 of human OR5H1 protein as immunogens, and are purified through affinity chromatography .

How does OR5H1 gene expression vary across different tissue types?

OR5H1, while traditionally associated with olfactory epithelium, demonstrates expression across multiple tissues based on transcriptomic studies. The expression pattern of OR5H1 extends beyond the nasal cavity to include low-level expression in various peripheral tissues. This ectopic expression suggests potential non-olfactory functions that remain to be fully characterized.

Recent research examining olfactory receptors in cancer contexts has shown that receptors like OR10H1 can influence tumor immunity and T-cell responses . By extension, OR5H1 may exhibit similar functional diversity across tissues, warranting comprehensive expression analysis in both healthy and diseased states. Research methodologies for such expression analysis would include quantitative PCR, RNA-seq, and immunohistochemistry using validated OR5H1 antibodies.

What are the optimal conditions for using OR5H1 antibodies in Western blot applications?

For optimal Western blot results with OR5H1 antibodies, researchers should implement the following protocol:

• Sample preparation: Prepare cell or tissue lysates in RIPA buffer supplemented with protease inhibitors. Include reducing agents such as β-mercaptoethanol in sample buffer.

• Protein separation: Use 10-12% SDS-PAGE gels to achieve optimal separation around the expected molecular weight range (observed: 72 kDa; calculated: 35.4 kDa). The discrepancy between observed and calculated weights suggests potential post-translational modifications that should be considered during analysis.

• Transfer conditions: Transfer proteins to PVDF membranes (0.45 μm pore size) using wet transfer at 100V for 60-90 minutes in cold transfer buffer containing 20% methanol.

• Blocking: Block membranes with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute OR5H1 antibody at 1:500-1:2000 in blocking buffer and incubate overnight at 4°C with gentle agitation. The optimal dilution should be determined empirically for each application .

• Secondary antibody: Use HRP-conjugated anti-rabbit secondary antibody at 1:5000-1:10000 dilution for 1 hour at room temperature.

• Detection: Develop using enhanced chemiluminescence substrate and expose to X-ray film or document using a digital imaging system.

When troubleshooting, researchers should be aware that the discrepancy between observed (72 kDa) and calculated (35.4 kDa) molecular weights may be due to post-translational modifications, particularly glycosylation, which is common in transmembrane proteins like olfactory receptors .

How should OR5H1 antibodies be optimized for immunofluorescence and immunocytochemistry?

For optimal immunofluorescence (IF) and immunocytochemistry (ICC) results with OR5H1 antibodies, follow these methodological guidelines:

• Cell/tissue preparation:

  • For cultured cells: Grow cells on poly-L-lysine coated coverslips and fix with 4% paraformaldehyde for 15 minutes at room temperature.

  • For tissue sections: Use freshly frozen or paraffin-embedded sections (4-6 μm thickness).

• Permeabilization: For intracellular epitopes, permeabilize with 0.1-0.3% Triton X-100 in PBS for 10 minutes. For membrane proteins like OR5H1, a milder permeabilization may be preferable (0.1% Triton X-100 for 5 minutes).

• Antigen retrieval: For paraffin sections, perform heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0).

• Blocking: Block with 5-10% normal serum (from the species of the secondary antibody) and 1% BSA in PBS for 1 hour at room temperature.

• Primary antibody incubation: Dilute OR5H1 antibody at 1:200-1:1000 in blocking buffer and incubate overnight at 4°C in a humidified chamber .

• Secondary antibody: Use fluorophore-conjugated anti-rabbit secondary antibodies (e.g., Alexa Fluor 488, 555, or 647) at manufacturer-recommended dilutions, typically 1:500-1:1000.

• Counterstaining and mounting: Counterstain nuclei with DAPI (1 μg/mL) and mount with an anti-fade mounting medium.

When validating staining specificity, always include appropriate controls:

• Primary antibody omission control

• Secondary antibody-only control

• Blocking peptide competition assay using the immunizing peptide (aa 262-311 of OR5H1)

OR5H1 should predominantly localize to the plasma membrane, with potential cytoplasmic distribution in the endoplasmic reticulum and Golgi due to protein processing and trafficking.

What are the recommended ELISA protocols for OR5H1 detection?

For developing robust ELISA assays using OR5H1 antibodies, researchers should consider the following protocol:

• Plate coating: Coat high-binding 96-well plates with OR5H1 antigen (recombinant protein or synthetic peptide) at 1-5 μg/ml in carbonate-bicarbonate buffer (pH 9.6) overnight at 4°C.

• Blocking: Block with 1-3% BSA in PBS for 1-2 hours at room temperature.

• Sample preparation: Prepare samples in blocking buffer or sample diluent compatible with the assay format.

• Primary antibody: For indirect ELISA, dilute OR5H1 antibody to 1:20,000 in appropriate diluent buffer and incubate for 1-2 hours at room temperature .

• Secondary antibody: Use HRP-conjugated anti-rabbit antibody at recommended dilution (typically 1:5000-1:10000) and incubate for 1 hour at room temperature.

• Detection: Add TMB substrate and stop the reaction with 2N H₂SO₄ after appropriate color development (typically 5-30 minutes). Read absorbance at 450 nm with 620 nm as reference wavelength.

For sandwich ELISA development:

• Use purified capture antibody (anti-OR5H1) at 1-5 μg/ml

• Apply samples containing OR5H1 protein

• Use biotinylated detection antibody followed by streptavidin-HRP

For electrochemiluminescence-based assays, following the methodology similar to that used in SARS-CoV-2 antibody detection studies , researchers can achieve enhanced sensitivity:

• Block antigen-coated plates with 5% BSA in PBS for 30 minutes

• Dilute samples serially (10 μg/mL to 0.1 pg/mL)

• Incubate with SULFO-TAG anti-human IgG antibody (1:200)

• Add read buffer immediately before measurement on a compatible plate reader

How can researchers address the discrepancy between observed and calculated molecular weights of OR5H1?

The observed molecular weight of OR5H1 in Western blot applications (approximately 72 kDa) differs significantly from its calculated molecular weight (35.4 kDa) . This discrepancy is common for membrane proteins, particularly GPCRs like olfactory receptors, and can be attributed to several factors:

• Post-translational modifications: OR5H1, like other GPCRs, likely undergoes extensive glycosylation, which can add substantial molecular weight. To confirm this:

  • Treat samples with glycosidases (PNGase F for N-linked or O-glycosidase for O-linked glycosylation) prior to Western blotting

  • Compare migration patterns before and after enzymatic treatment

  • A significant reduction in apparent molecular weight after treatment would confirm glycosylation

• Protein aggregation: Membrane proteins can form SDS-resistant aggregates. To address this:

  • Optimize sample preparation by varying detergent concentrations

  • Test different reducing agent concentrations

  • Consider alternative lysis buffers specifically designed for membrane proteins

• Technical considerations:

  • Use gradient gels (4-20%) to better resolve proteins across a wide molecular weight range

  • Include known molecular weight markers alongside your samples

  • Validate antibody specificity using knockout/knockdown controls or blocking peptides

• Protein isoforms: Check databases for potential alternative splice variants or isoforms of OR5H1 that might account for size differences.

When reporting results, always document both the observed and expected molecular weights, and consider including supporting evidence from orthogonal methods such as mass spectrometry to definitively characterize the detected OR5H1 protein.

What controls should be included when validating OR5H1 antibody specificity?

Rigorous validation of OR5H1 antibody specificity is essential for generating reliable research data. Researchers should implement the following controls:

• Genetic controls:

  • OR5H1 knockout or knockdown (siRNA/shRNA) samples compared to wild-type

  • OR5H1 overexpression systems (transient or stable transfection)

  • These controls provide the strongest evidence for antibody specificity

• Peptide competition assays:

  • Pre-incubate the OR5H1 antibody with excess immunizing peptide (aa 262-311)

  • Run parallel Western blots or immunostaining with competed and non-competed antibody

  • Specific signal should be abolished or significantly reduced after peptide competition

• Cross-reactivity assessment:

  • Test the antibody on tissues/cells known to lack OR5H1 expression

  • Evaluate potential cross-reactivity with other olfactory receptors, particularly those with sequence homology to the immunogen region

• Multiple antibody validation:

  • Compare results using antibodies from different sources or those targeting different epitopes of OR5H1

  • Concordant results with multiple antibodies increase confidence in specificity

• Orthogonal methods:

  • Confirm protein expression using independent techniques (e.g., mass spectrometry)

  • Correlate protein detection with mRNA expression data (qPCR, RNA-seq)

• Technical controls:

  • Include secondary antibody-only controls to assess non-specific binding

  • Use appropriate isotype controls for IgG background signal assessment

Documentation of these validation steps should be included in publications to increase result reproducibility and reliability.

How should researchers interpret OR5H1 expression data in different experimental contexts?

Interpreting OR5H1 expression data requires consideration of multiple factors across different experimental approaches:

• Western blot interpretation:

  • Always note the molecular weight(s) of detected bands (expect ~72 kDa)

  • Quantify relative expression using appropriate loading controls (β-actin, GAPDH)

  • For membrane proteins like OR5H1, consider Na⁺/K⁺-ATPase or cadherin as more appropriate loading controls

  • Be aware that expression levels may vary significantly between tissue types

• Immunohistochemistry/Immunofluorescence interpretation:

  • Document subcellular localization (primarily membrane-associated)

  • Note any heterogeneity in expression within tissues

  • Quantify staining intensity using standardized scoring systems or digital image analysis

  • Compare distribution patterns with known olfactory receptor trafficking pathways

• qPCR/RNA-seq data interpretation:

  • Normalize gene expression to appropriate reference genes

  • Be aware that mRNA levels may not directly correlate with protein expression

  • Consider using multiple primers targeting different exons to detect potential splice variants

• Functional studies interpretation:

  • When studying OR5H1 in non-olfactory contexts, consider its potential role in signal transduction pathways similar to what has been observed with OR10H1 in immune regulation

  • Correlate expression data with functional readouts (cAMP levels, calcium signaling, etc.)

  • Consider cell type-specific effects and potential interactions with other signaling pathways

• Cross-species considerations:

  • When comparing expression between human, mouse, and rat samples, account for species-specific differences in OR5H1 sequence and function

  • Use species-matched positive controls for accurate interpretation

When encountering unexpected expression patterns or localization, verify findings using alternative detection methods and consider the possibility of context-dependent regulation or novel functions of OR5H1 beyond classical olfactory roles.

How can OR5H1 antibodies be utilized in investigating potential immune checkpoint functions?

Recent research on the related olfactory receptor OR10H1 has revealed its function as an immune checkpoint in the tumor microenvironment . This finding opens avenues for investigating similar roles for OR5H1, using antibodies as key research tools:

• Co-immunoprecipitation (Co-IP) studies:

  • Use OR5H1 antibodies to pull down protein complexes

  • Analyze binding partners through mass spectrometry

  • Focus on interactions with immune signaling components

  • Recommended protocol: Crosslink OR5H1 antibody to Protein A/G beads, incubate with cell lysates, wash stringently, and elute for analysis

• Proximity ligation assays (PLA):

  • Combine OR5H1 antibodies with antibodies against suspected interaction partners

  • Visualize protein-protein interactions in situ

  • Quantify interaction events in different cellular contexts

• Functional blockade experiments:

  • Apply OR5H1 antibodies to live cells to potentially block receptor function

  • Measure impacts on cAMP signaling, similar to the cAMP-dependent signaling described for OR10H1

  • Monitor downstream effects on protein kinase A (PKA) and C-terminal Src kinase (Csk) activation

• T cell activation assays:

  • Co-culture OR5H1-expressing cells with T cells in the presence/absence of blocking antibodies

  • Measure T cell activation markers (CD69, CD25), cytokine production, and proliferation

  • Assess T cell apoptosis rates, similar to the reduced T cell apoptosis observed with OR10H1 deficiency

• In vivo studies:

  • Use OR5H1 antibodies to perform immunohistochemical analysis of tumor-infiltrating lymphocytes (TILs) in relation to OR5H1 expression

  • Consider xenograft models with adoptive T cell transfer to evaluate in vivo relevance, following methodologies similar to those used for OR10H1

These approaches can help determine whether OR5H1, like OR10H1, modulates tumor immunity through cAMP-dependent mechanisms affecting T cell function and survival.

What are the considerations for developing phospho-specific OR5H1 antibodies for signaling studies?

Developing phospho-specific antibodies against OR5H1 requires careful consideration of several key factors:

• Phosphorylation site identification:

  • Perform in silico analysis of OR5H1 sequence to identify potential phosphorylation sites

  • Focus on intracellular loops and C-terminal domains, which are common phosphorylation regions in GPCRs

  • Confirm predicted sites through mass spectrometry analysis of OR5H1 immunoprecipitated from cells under basal and stimulated conditions

• Phosphopeptide design for immunization:

  • Synthesize phosphopeptides corresponding to identified phosphorylation sites

  • Include 10-15 amino acids surrounding the phosphosite

  • Ensure appropriate conjugation to carrier proteins (KLH or BSA)

  • Consider dual immunization strategies using both phosphorylated and non-phosphorylated peptides for later antibody purification

• Antibody purification strategy:

  • Implement sequential affinity purification using both phospho and non-phospho peptide columns

  • First remove antibodies recognizing non-phosphorylated epitopes

  • Then positively select antibodies specific to the phosphorylated form

  • Test for cross-reactivity against other phosphorylated proteins, particularly other olfactory receptors

• Validation protocols:

  • Demonstrate phosphorylation specificity using phosphatase-treated samples

  • Verify specificity using site-directed mutagenesis (changing the phosphorylatable residue to alanine)

  • Confirm kinase dependency by using specific kinase inhibitors or activators

  • Test antibody performance in multiple applications (WB, IF, IHC, ELISA)

• Experimental applications:

  • Use phospho-specific antibodies to monitor OR5H1 activation states

  • Investigate kinase pathways regulating OR5H1 phosphorylation

  • Study temporal dynamics of phosphorylation in response to stimuli

  • Correlate phosphorylation status with downstream signaling events such as cAMP production or calcium mobilization

The development of phospho-specific OR5H1 antibodies would significantly advance the field's understanding of how this receptor is regulated in various physiological and pathological contexts.

How can researchers utilize OR5H1 antibodies in structural biology and receptor trafficking studies?

OR5H1 antibodies can be powerful tools for investigating the structural biology and trafficking dynamics of this olfactory receptor:

• Structural studies:

  • Use OR5H1 antibodies for immunoaffinity purification to obtain pure receptor protein for crystallography or cryo-EM studies

  • Generate Fab fragments from OR5H1 antibodies to stabilize receptor conformations

  • Implement conformational state-specific antibodies that recognize active versus inactive receptor states

  • Consider OR5H1 antibodies as tools for co-crystallization to stabilize specific protein conformations

• Receptor trafficking dynamics:

  • Employ live-cell imaging with fluorescently labeled non-perturbing OR5H1 antibody fragments

  • Track receptor internalization and recycling using pulse-chase experiments with antibodies

  • Develop antibodies recognizing specific post-translational modifications that correlate with trafficking states

  • Protocol recommendation: Surface labeling of live cells with OR5H1 antibodies at 4°C, followed by temperature shift to 37°C to initiate internalization, with imaging at defined timepoints

• Protein-protein interaction mapping:

  • Utilize OR5H1 antibodies in crosslinking mass spectrometry approaches

  • Implement proximity-dependent labeling methods (BioID, APEX) followed by OR5H1 immunoprecipitation

  • Perform super-resolution microscopy with OR5H1 antibodies to visualize nanoscale organization at the membrane

• Oligomerization studies:

  • Apply OR5H1 antibodies in native PAGE analysis following mild detergent solubilization

  • Perform fluorescence resonance energy transfer (FRET) studies using labeled antibodies

  • Investigate potential homo- and hetero-oligomerization with other olfactory receptors or GPCRs

• Membrane microdomain localization:

  • Use OR5H1 antibodies in detergent-resistant membrane fractionation studies

  • Perform co-localization analysis with lipid raft markers

  • Investigate the impact of membrane composition on OR5H1 distribution and function

These approaches can provide crucial insights into OR5H1 biology beyond simple expression analysis, advancing our understanding of its structure-function relationships and cellular dynamics.

What role might OR5H1 play in tumor immunology based on findings from related olfactory receptors?

The discovery that the olfactory receptor OR10H1 functions as an immune checkpoint in the tumor microenvironment suggests potential parallel roles for OR5H1 in tumor immunology:

• Potential mechanistic similarities:

  • Like OR10H1, OR5H1 may influence cAMP-dependent signaling within T cells

  • This signaling could modulate PKA activation and subsequent Csk-mediated inhibition of T cell receptor signaling

  • The net effect may be suppression of T cell-mediated anti-tumor responses

• Experimental approaches to investigate OR5H1 in tumor immunity:

  • Screen for OR5H1 expression across tumor types using immunohistochemistry with validated antibodies

  • Correlate expression with tumor-infiltrating lymphocyte (TIL) density and activation status

  • Perform OR5H1 knockdown/knockout studies in tumor cell lines followed by co-culture with TILs

  • Measure T cell effector functions (cytokine production, cytotoxicity) and apoptosis rates

  • Implement xenograft models with OR5H1-deficient tumors and adoptive T cell transfer

• Potential therapeutic implications:

  • If validated as an immune checkpoint, OR5H1-blocking antibodies could be developed as immunotherapeutic agents

  • These could potentially complement existing checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4

  • Combined blockade strategies could be explored to overcome resistance to current immunotherapies

• Biomarker potential:

  • OR5H1 expression could serve as a predictive biomarker for immunotherapy response

  • Immunohistochemical detection using validated antibodies could be implemented in patient stratification

This research direction represents a significant opportunity to expand our understanding of non-canonical immune checkpoints and potentially identify novel therapeutic targets for cancer immunotherapy.

How can multiplexed antibody methods be applied to study OR5H1 in relation to other olfactory receptors?

Advanced multiplexed approaches using OR5H1 antibodies can reveal complex relationships between multiple olfactory receptors and their signaling networks:

• Multiplex immunofluorescence techniques:

  • Implement tyramide signal amplification (TSA) multiplexing to simultaneously detect 5-7 olfactory receptors including OR5H1

  • Use spectral unmixing to resolve overlapping fluorophore emissions

  • Apply this approach to analyze co-expression patterns across tissues

  • Quantify relative expression levels and subcellular localization of multiple receptors

• Mass cytometry (CyTOF) applications:

  • Conjugate OR5H1 antibodies with rare earth metals

  • Combine with antibodies against other olfactory receptors and signaling molecules

  • Analyze at single-cell resolution to identify receptor co-expression patterns

  • Correlate with activation states of various signaling pathways

• Spatial transcriptomics integration:

  • Combine OR5H1 antibody-based protein detection with spatial transcriptomics

  • Map protein expression to corresponding mRNA localization

  • Identify potential post-transcriptional regulation mechanisms

  • Create comprehensive spatial maps of olfactory receptor expression

• Proximity ligation assay (PLA) networks:

  • Detect physical interactions between OR5H1 and other membrane proteins

  • Implement multiplexed PLA to map interaction networks

  • Visualize receptor clustering and heteromeric complex formation

  • Correlate with functional outcomes in different cellular contexts

• Single-molecule localization microscopy:

  • Apply super-resolution techniques (STORM, PALM) using OR5H1 antibodies

  • Investigate nanoscale organization of receptor clusters

  • Analyze co-clustering with other olfactory receptors and signaling components

  • Study dynamic reorganization following stimulation

These multiplexed approaches can reveal previously unappreciated relationships between OR5H1 and other receptors, potentially uncovering functional receptor networks that coordinate responses to diverse stimuli.

What are the considerations for developing OR5H1 antibodies for therapeutic applications?

While the current focus of OR5H1 antibodies is on research applications, emerging evidence about olfactory receptors in non-olfactory contexts suggests potential therapeutic applications. Developing OR5H1 antibodies for therapeutic use would require addressing several critical considerations:

• Therapeutic target validation:

  • Establish clear disease relevance through rigorous target validation studies

  • Determine whether OR5H1 blockade or activation would be therapeutically beneficial

  • If findings with OR10H1 in tumor immunity extend to OR5H1, focus on antibodies that block receptor function

  • Confirm target engagement leads to desired functional outcomes in disease-relevant models

• Antibody format selection:

  • Consider various formats: conventional IgG, Fab fragments, single-chain antibodies, bispecifics

  • For membrane proteins like OR5H1, accessibility of epitopes in the native conformation is crucial

  • Evaluate whether intracellular delivery would be necessary (using cell-penetrating antibodies)

  • Select format based on required pharmacokinetics and tissue penetration properties

• Humanization and optimization:

  • Convert rabbit-derived research antibodies to humanized versions to reduce immunogenicity

  • Optimize affinity while maintaining specificity

  • Engineer Fc regions for desired effector functions or extended half-life

  • Consider antibody-drug conjugates if targeted cellular delivery is desired

• Manufacturing considerations:

  • Develop stable cell lines for consistent production

  • Implement robust purification processes that maintain critical quality attributes

  • Establish appropriate formulation for stability and delivery

  • Define critical quality attributes and implement appropriate analytical methods

• Preclinical development pathway:

  • Design toxicology studies considering on-target and off-target effects

  • Assess potential cross-reactivity with other olfactory receptors

  • Develop appropriate biomarkers to track target engagement

  • Establish pharmacokinetic/pharmacodynamic relationships

The path from research antibodies to therapeutic candidates is complex, but with emerging roles for olfactory receptors in disease contexts, OR5H1-targeted antibody therapeutics could represent a novel intervention strategy worth exploring.